Fuqiang Hu
- Pharmaceutical Science top 0.02%
- Advanced Drug Delivery Systems 41
- Advancements in Transdermal Drug Delivery 24
- Drug Solubulity and Delivery Systems 17
- Biomaterials top 0.1%
- Nanoparticle-Based Drug Delivery 82
- Molecular Medicine top 1%
- Biomedical Engineering top 0.5%
- Nanoplatforms for cancer theranostics 50
- Molecular Biology top 2%
- RNA Interference and Gene Delivery 53
- Lipid Membrane Structure and Behavior 23
- Advanced biosensing and bioanalysis techniques 18
- Journals
- International Journal of Pharmaceutics (22 papers)International Journal of Nanomedicine (16 papers)Molecular Pharmaceutics (12 papers)
- Partner nations
- ChinaCzechiaUnited States
In The Last Decade
Fuqiang Hu
199 papers receiving 9.1k citations
Hit Papers
Peers
Comparison fields: 5 of 136
- Pharmaceutical Science 3.1k
- Biomaterials 3.8k
- Molecular Medicine 435
- Biomedical Engineering 2.5k
- Molecular Biology 3.6k
Countries citing papers authored by Fuqiang Hu
This map shows the geographic impact of Fuqiang Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fuqiang Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fuqiang Hu more than expected).
Fields of papers citing papers by Fuqiang Hu
This network shows the impact of papers produced by Fuqiang Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fuqiang Hu. The network helps show where Fuqiang Hu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fuqiang Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 10 | |
| 4 | 2024 | 7 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 21 | |
| 7 | 2023 | 13 | |
| 8 | 2023 | 1 | |
| 9 | 2022 | 6 | |
| 10 | 2021 | 28 | |
| 11 | 2020 | 10 | |
| 12 | 2020 | 7 | |
| 13 | 2020 | 60 | |
| 14 | 2020 | 22 | |
| 15 | 2019 | 32 | |
| 16 | 2018 | 12 | |
| 17 | 2018 | 19 | |
| 18 | 2018 | 30 | |
| 19 | 2018 | 51 | |
| 20 | Knockdown of the inflammatory factor pentraxin-3 suppresses growth and invasion of lung adenocarcinoma through the AKT and NF-kappa B pathways. | 2015 | 16 |
About Fuqiang Hu
Fuqiang Hu is a scholar working on Pharmaceutical Science, Biomaterials and Molecular Biology, having authored 203 papers that have together received 9.2k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (82 papers), RNA Interference and Gene Delivery (53 papers), Nanoplatforms for cancer theranostics (50 papers), Advanced Drug Delivery Systems (41 papers), Advancements in Transdermal Drug Delivery (24 papers), Lipid Membrane Structure and Behavior (23 papers), Advanced biosensing and bioanalysis techniques (18 papers) and Drug Solubulity and Delivery Systems (17 papers). The work is most often cited by research in Pharmaceutical Science (3.1k citations), Biomaterials (3.8k citations) and Molecular Medicine (435 citations). Fuqiang Hu has collaborated with scholars based in China, Czechia and United States. Frequent co-authors include Hong Yuan, Yongzhong Du, Jian You, Su Zeng, Hong Yuan, Wei Wu, Tingting Meng, Yi Lü, Yi-Qing Ye and Saiping Jiang. Their work appears in journals such as International Journal of Pharmaceutics, International Journal of Nanomedicine, Molecular Pharmaceutics, Colloids and Surfaces B Biointerfaces and Biomaterials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.